Vol. 6 No. 2 (2026)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published February 6, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pembrolizumab (Keytruda), 100 mg/4 mL vial, solution for infusion.
  • Indication: For the treatment of FIGO 2014 stage III to IVA cervical cancer, patients should receive pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity or up to 24 months. Pembrolizumab should be administered before chemoradiotherapy when given on the same day.